Tirzepatide
- Category
- Weight Management & Metabolic
- Administration routes
- Injectable
- Regulatory status
- FDA-approved
What it is
A dual GIP/GLP-1 receptor agonist used for weight loss and metabolic health. Human evidence is strong: trials show superior weight loss, glycemic control, and heart failure benefit, with softer data on cardiovascular risk. GI side effects are common, and a boxed warning for thyroid tumors in animal studies rules it out for anyone with a history of medullary thyroid cancer or MEN 2. It is FDA-approved, sold as a regulated pharmaceutical, not research-grade.
Read Full recordStudied uses & evidence
Studied uses(8)
Superior weight loss
HighMultiple large RCTs showed 15-21% weight loss, exceeding semaglutide in a head-to-head trial.
Glycemic control
HighMultiple phase 3 trials showed HbA1c reductions of 2-2.6 points, beating semaglutide and insulin.
T2D prevention
HighSingle large trial found a 93% reduction in diabetes progression among adults with prediabetes.
Evidence limits
- Evidence Level
- Level 1 — Strong
600+ PubMed studies. 35,000+ participants across SURPASS (T2DM), SURMOUNT (obesity), SUMMIT (HFpEF), SYNERGY-NASH, SURMOUNT-OSA programs. SURPASS-CVOT alone had 13,000+ patients over 4+ years.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Personal/family history of medullary thyroid carcinoma
AbsoluteSame thyroid C-cell tumor risk as other incretin-based therapies. Contraindicated in MTC/MEN2.
History of pancreatitis
HighMonitor closely. Discontinue if pancreatitis suspected.
Severe gastroparesis
HighDual GIP/GLP-1 action significantly slows gastric emptying.
General cautions
Pregnancy
AbsoluteDo not use during pregnancy. MHRA guidance recommends stopping tirzepatide at least 1 month before a planned pregnancy.
Risk summary(6)
Risks = level of concern: High · Moderate · Low · Theoretical
GI side effects: nausea (13-24%), diarrhea (13-21%), vomiting (6-14%)
HighBoxed warning: thyroid C-cell tumors in animal studies
ModeratePancreatitis risk (rare)
LowGallbladder disease
ModeratePotential for hypoglycemia when combined with insulin or sulfonylureas
ModerateContraindicated: personal/family history of medullary thyroid carcinoma or MEN 2
High
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Prescribing labels in Full record
- Monitoring & labs in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.